USPTO serial 88589105
LINNEA 315CSE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 18, 2021
- Examiner
- JOHNSON, AISHA CLARKE
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with LINNEA 315CSE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Riazzino, CH
Riazzino, CH
Riazzino, CH
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Perla M. Kuhn
Perla M. Kuhn FOX ROTHSCHILD LLP997 LENOX DRIVE, BUILDING 3PRINCETON PIKE CORPORATE CENTERLAWRENCEVILLE, NJ 08648-2311Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical additives for use in the manufacture of pharmaceuticals; botanical extracts, active substances and active chemical ingredients for use in the manufacture of pharmaceuticals; botanical extracts, active substances and active chemical ingredients for use in the manufacture of medicines for treating skin diseases, neuropathic pain, cancer pain, autoimmune diseases, anorexia, AIDS, psychiatric disorders, neurovegetative disorders, metabolic disorders, cardiovascular disorders, respiratory diseases, gastrointestinal disorders, disorders of the central nervous system, disorders of the immune system; botanical extracts, active substances and active chemical ingredients for use in the manufacture of veterinary preparations; plant extracts, active compounds and active chemical ingredients for use in the manufacture of pharmaceuticals; plant extracts, active substances and active chemical ingredients for use in the manufacture of medicines for treating skin diseases, neuropathic pain, cancer pain, autoimmune diseases, anorexia, AIDS, psychiatric disorders, neurovegetative disorders, metabolic disorders, cardiovascular disorders, respiratory diseases, gastrointestinal disorders, disorders of the central nervous system, disorders of the immune system; chemicals for use in the manufacture of cosmetics and food; botanical extracts for use in the manufacture of cosmetics and food; botanical extracts for use in the manufacture of cosmetics and dietary supplements; food preserving chemicals; plant extracts, active substances and active chemical ingredients for use in the manufacture of cosmetics and dietary supplements | ACTIVE | — |
| 005 | Pharmaceuticals derived from botanical and plant extracts; pharmaceuticals derived from botanical and plant extracts for veterinary purposes; pharmaceuticals derived from botanical and plant extracts for use in the treatment of skin diseases, neuropathic pain, cancer pain, autoimmune diseases, anorexia, AIDS, psychiatric disorders, neurovegetative disorders, metabolic disorders, cardiovascular disorders, respiratory diseases, gastrointestinal disorders, disorders of the central nervous system, disorders of the immune system; medicines for veterinary purposes; dietary supplements based on botanical and plant extracts; dietary supplements based on botanical and plant extracts for pharmaceutical and veterinary purposes; dietary supplements based on botanical and plant extracts in the form of pharmaceuticals for treating skin diseases, neuropathic pain, cancer pain, autoimmune diseases, anorexia, AIDS, psychiatric disorders, neurovegetative disorders, metabolic disorders, cardiovascular disorders, respiratory diseases, gastrointestinal disorders, disorders of the central nervous system, disorders of the immune system; plant extracts, active substances and active chemical ingredients for veterinary use; plant extracts, active substances and active chemical ingredients for use in the pharmaceutical industry; plant extracts, active substances and active chemical ingredients for use in the cosmetics industry; chemical preparations for pharmaceutical or medical purposes, namely, for use in the treatment of skin diseases, neuropathic pain, cancer pain, autoimmune diseases, anorexia, AIDS, psychiatric disorders, neurovegetative disorders, metabolic disorders, cardiovascular disorders, respiratory diseases, gastrointestinal disorders, disorders of the central nervous system, disorders of the immune system | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 18, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 29, 2025 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Sep 26, 2024 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Sep 23, 2024 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Sep 12, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 6, 2024 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| May 18, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 9, 2021 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Apr 9, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 20, 2021 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jan 20, 2021 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Sep 15, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 21, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 16, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 11, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 11, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 11, 2020 | ALIE | ASSIGNED TO LIE | — |
| Jun 3, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 4, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 4, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 4, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 21, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 9, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 26, 2019 | NWAP | NEW APPLICATION ENTERED | — |